Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Ascenta Signs Cancer Drug Deal with Ascentage, Its China Spin-off

publication date: Dec 2, 2010
Ascenta Therapeutics of the US has struck a deal to co-develop cancer drugs with Ascentage Pharma Group, a company with operations in Hong Kong and Shanghai. As the names suggest, the two companies are closely related. Ascentage was Ascenta’s R&D operation in China until it was spun off last year. The companies contend their collaboration will use each entity’s complementary strengths and speed up the process of regulatory review. More details....


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China